Opioids for the management of breakthrough cancer pain in adults: A systematic review undertaken as part of an EPCRC opioid guidelines project

Palliative Medicine

Volumn 25, Issue 5, 2011, Pages 516-524

  Zeppetella, Giovambattista ^a  

^a FRCP   (United Kingdom)

Author keywords

breakthrough pain; Neplasm; opioids; pain; transmucosal

Indexed keywords

FENTANYL; FENTANYL CITRATE; HYDROCODONE; HYDROMORPHONE; MORPHINE; OPIATE; OXYCODONE; PLACEBO;

ASTHENIA; CANCER PAIN; CANCER PALLIATIVE THERAPY; CONFERENCE PAPER; CONFUSION; CONSTIPATION; DIZZINESS; DROWSINESS; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; HEADACHE; HUMAN; NAUSEA; OUTCOME ASSESSMENT; PAIN ASSESSMENT; PATIENT SATISFACTION; PRACTICE GUIDELINE; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SOMNOLENCE; SYSTEMATIC REVIEW; TIME TO MAXIMUM PLASMA CONCENTRATION; VOMITING;

ADMINISTRATION, ORAL; ANALGESICS, OPIOID; BREAKTHROUGH PAIN; EUROPE; FENTANYL; HUMANS; NEOPLASMS; PAIN MEASUREMENT; PRACTICE GUIDELINES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 79959890347     PISSN: 02692163     EISSN: 1477030X     Source Type: Journal    
DOI: 10.1177/0269216310385601     Document Type: Conference Paper

References (17)

1. Portenoy RK, Hagen NA. Breakthrough pain: definition, prevalence and characteristics. Pain. 1990 ; 41: 273-281 (Pubitemid 20187930)
2. Caraceni A, Portenoy RK. An international survey of cancer pain characteristics and syndromes: IASP Task Force on Cancer Pain. International Association for the Study of Pain. Pain. 1999 ; 82: 263-274
3. Hanks GW, de Conno F, Cherny N, et al. Morphine and alternative opioids in cancer pain: the EAPC recommendations. Br J Cancer. 2001 ; 84: 587-593 (Pubitemid 32238990)
4. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports on randomised clinical trials: is blinding necessary?. Control Clin Trials. 1996 ; 17: 1-12 (Pubitemid 26120810)
5. Farrar JT, Cleary J, Rauck R, Busch M, Nordbrock E. Oral transmucosal fentanyl citrate: randomized, double-blinded, placebo-controlled trial for treatment of breakthrough pain in cancer patients. J Natl Cancer Inst. 1998 ; 90: 611-616 (Pubitemid 28204805)
6. Christie JM, Simmonds M, Patt R, et al. Dose-titration, multicenter study of oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients using transdermal fentanyl for persistent pain. J Clin Oncol. 1998 ; 16: 3238-3245 (Pubitemid 28481617)
7. Portenoy RK, Payne R, Coluzzi P, et al. Oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in cancer patients: a controlled dose titration study. Pain. 1999 ; 79: 303-312 (Pubitemid 29076765)
8. Coluzzi PH, Schwartzberg L, Conroy JD, et al. Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR). Citation: Pain. 2001 ; 91: 123-130 (Pubitemid 32274181)
9. Portenoy RK, Taylor D, Messina J, Tremmel L. A randomized, placebo-controlled study of fentanyl buccal tablet for breakthrough pain in opioid-treated patients with cancer. Clin J Pain. 2006 ; 22: 805-811 (Pubitemid 44627444)
10. Mercadante S, Villari P, Ferrera P, Casuccio A, Mangione S, Intravaia G. Transmucosal fentanyl vs intravenous morphine in doses proportional to basal opioid regimen for episodic-breakthrough pain. Br J Cancer. 2007 ; 96: 1828-1833 (Pubitemid 46912022)
11. Slatkin NE, Xie F, Messina J, Segal TJ. Fentanyl buccal tablet for relief of breakthrough pain in opioid-tolerant patients with cancer-related chronic pain. J Supp Oncol. 2007 ; 5: 327-334 (Pubitemid 350055013)
12. Kress HG, Orońska A, Kaczmarek Z, Kaasa S, Colberg T, Nolte T. Efficacy and tolerability of intranasal fentanyl spray 50 to 200 microg for breakthrough pain in patients with cancer: a phase III, multinational, randomized, double-blind, placebo-controlled, crossover trial with a 10-month, open-label extension treatment period. Clin Ther. 2009 ; 31: 1177-1191
13. Hanks G. Oral transmucosal fentanyl citrate for the management of breakthrough pain. Eur J Pall Care. 2001 ; 8: 6-9
14. Darwish M, Kirby M, Robertson P, Tracewell W, Jiang JG. Absolute and relative bioavailability of fentanyl buccal tablet and oral transmucosal fentanyl citrate. J Clin Pharmacol. 2007 ; 47: 343-350 (Pubitemid 46294716)
15. Christrup LL, Foster D, Popper LD, Troen T, Upton R. Pharmacokinetics, efficacy, and tolerability of fentanyl following intranasal versus intravenous administration in adults undergoing third-molar extraction: a randomized, double-blind, double-dummy, two-way, crossover study. Clin Ther. 2008 ; 30: 469-481 (Pubitemid 351483922)
16. Zeppetella G. Impact and management of breakthrough pain in cancer. Curr Opin Support Palliat Care. 2009 ; 3: 1-6
17. Davies AN, Dickman A, Reid C, Stevens AM, Zeppetella G. The management of cancer-related breakthrough pain: recommendations of a task group of the Science Committee of the Association for Palliative Medicine of Great Britain and Ireland. Eur J Pain. 2009 ; 13: 331-338